Profile Response Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

Molecular Profile Unknown unknown
Therapy GC1118
Indication/Tumor Type colorectal cancer
Response Type not applicable


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown colorectal cancer not applicable GC1118 Phase I Actionable In a Phase I clinical trial, treatment with GC1118 resulted in no responses, but stable disease in 58% (7/12), and a median progression-free survival (PFS) of 14 weeks in patients with metastatic colorectal cancer with no prior anti-EGFR therapy, and resulted in an overall response rate of 17% (2/12; all partial responses), stable disease in 8% (1/12), and median PFS of 6.9 weeks in patients with metastatic colorectal cancer with resistance to anti-EGFR therapy (PMID: 31164456; NCT02352571). 31164456
PubMed Id Reference Title Details
(31164456) A First-in-Human Phase I Study of GC1118, a Novel Anti-Epidermal Growth Factor Receptor Antibody, in Patients with Advanced Solid Tumors. Full reference...